Telo GenomicsTDSGF +3.71% Quick Ratio is 0.49 as of Mar. 2026, which is 87% below its 10-year median of 3.75. The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Telo Genomics ranks worse than 90.65% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Telo Genomics's quick ratio for the quarter that ended in Mar. 2026 was 0.49.
Telo Genomics has a quick ratio of 0.49. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Telo Genomics's Quick Ratio or its related term are showing as below:
TDSGF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.06 Med: 3.75 Max: 97.13
Current: 0.49
During the past 13 years, Telo Genomics's highest Quick Ratio was 97.13. The lowest was 0.06. And the median was 3.75.
TDSGF's Quick Ratio is ranked worse than 90.65% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.69
vs TDSGF: 0.49
Telo Genomics (OTCPK:TDSGF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Telo Genomics Quick Ratio Related Terms
Telo Genomics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Telo Genomics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Telo Genomics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telo Genomics Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Telo Genomics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Telo Genomics's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telo Genomics (TDSGF) has a Quick Ratio of 0.49 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Telo Genomics and its competitors. This is 87% below median its historical median of 3.75. Over the past decade, Telo Genomics' Quick Ratio has ranged from 0.06 to 97.13. According to the industry distribution chart, Telo Genomics ranks #194 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 90.7%.
Is Telo Genomics' Quick Ratio too high?
Telo Genomics' current Quick Ratio of 0.49 is 87% below median its 10-year median of 3.75. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 97.13. The Medical Diagnostics & Research industry median Quick Ratio is 1.69. Telo Genomics' value of 0.49 is 71% below this industry median. Based on the distribution chart, Telo Genomics ranks #194 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Telo Genomics' Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #194 out of 214 companies for Quick Ratio. This places Telo Genomics in the lower half of its industry. The industry median Quick Ratio is 1.69. Telo Genomics' value of 0.49 is 71% below this benchmark. Historically, Telo Genomics' own Quick Ratio has ranged from 0.06 to 97.13 over the past decade. While the company's 10-year median is 3.75 vs. the industry median of 1.69, Telo Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.69, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telo Genomics's current Quick Ratio of 0.49 is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Telo Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telo Genomics's current Quick Ratio is 0.49, which is 87% below median its own 10-year median of 3.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current Quick Ratio of 0.49. The current Quick Ratio is 0.49, which is 87% below median its 10-year median of 3.75 and 71% below the Medical Diagnostics & Research industry median of 1.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current Quick Ratio is 0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TDSGF has been successfully added to your 